Intellia Therapeutics Appoints Caroline Dorsa To Company’s Board Of Directors
Former Chief Financial Officer Brings 30 Years of Business Leadership and Board of Directors' Experience
CAMBRIDGE, MASS. – December 14, 2015 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Caroline Dorsa to its Board of Directors. Both as a director and business leader, Ms. Dorsa brings over 30 years of diverse experience and management in the public sector and regulated industries, including energy, pharmaceuticals and telecommunications.
Ms. Dorsa has held a number of senior-management positions at Merck & Co., Inc., including Vice President and Treasurer where she also oversaw tax, financial planning for manufacturing and investor relations. Most recently, as Executive Vice President and CFO at Public Service Enterprise Group, Ms. Dorsa led the finance, business development and investor relations teams, delivering solid financial performance through a challenging period in the energy markets. She is a director of Biogen Inc.
"We are excited to have Caroline join our Board of Directors at such an important stage in Intellia's growth and during the rapid acceleration of the gene-editing industry," says Nessan Bermingham, Ph.D., Founder and Chief Executive Officer, Intellia Therapeutics. "We are fortunate to benefit from her extensive board and business experience, particularly in finance, corporate governance, risk management and compensation, as we grow a sustainable company with transformational treatments for patients."
"I am pleased to join Intellia's Board of Directors and to help advance the company's mission of developing therapeutics utilizing CRISPR/Cas9 gene-editing technology," says Caroline Dorsa, member of board of directors, Intellia Therapeutics. "The Intellia team is extraordinarily committed and aligned on the path to bring potential cures to patients."
About Intellia Therapeutics
Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. Intellia intends to advance its pipeline and potentially develop a new drug class by leveraging its leading scientific and clinical development expertise and its exclusive access to one of the most comprehensive intellectual property platforms available. Intellia is supported by its founding investors Atlas and Novartis, as well a number of public and private sector funds. In 2014, Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a "Fierce 15" biotech company by FierceBiotech. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Jennifer Mound Smoter
Chief External Affairs & Communications Officer